Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Post by SundayMovieson Dec 08, 2022 10:20am
194 Views
Post# 35158877

Okay Hostile Take Over

Okay Hostile Take OverI hope the market push the market cap to 350-400 millions range so that we can refinanced.
Otherwise, we will have to accept a lowball partnership offer for either pancreatic or breast cancer...

On the flip side, this company is so so so vulnerabel now for a hostile take over.
You got now 3 different trials indicating potential cure for cancer...

Skin cancer 3years+ survival (market has forgotten this one)
Goblet 1 - Patient 013 got a complet response
Adlai (dosage escalation trial) Yup in a boring dosage escation we got 1 PR and still alive after one year...

Time to unload your crypto zeros and buy this company up. Otherwise, we get an hostile low ball take over in the coming weeks...

Anyway, because the shareholders are so depressed beyond hope. A hostile take over would work here.

I be sad (hostile take over) but still very happy to with my return on investment... So, please do it (AstraZeneca). I would tender my shares.
<< Previous
Bullboard Posts
Next >>